Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Expenses

Vertex vs. CRISPR: A Decade of Cost Dynamics

__timestampCRISPR Therapeutics AGVertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014151300060987000
Thursday, January 1, 201512573000125542000
Friday, January 1, 201642238000210460000
Sunday, January 1, 201769800000275119000
Monday, January 1, 2018113773000409539000
Tuesday, January 1, 2019179362000547758000
Wednesday, January 1, 2020269407000736300000
Friday, January 1, 202117953000904200000
Saturday, January 1, 20221102500001080300000
Sunday, January 1, 20231302500001262200000
Monday, January 1, 2024-23140001530500000
Loading chart...

Unlocking the unknown

Cost Insights: Vertex Pharmaceuticals vs. CRISPR Therapeutics

In the ever-evolving landscape of biotechnology, understanding the financial dynamics of leading companies is crucial. Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG, two giants in the field, have shown distinct trends in their cost of revenue over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has consistently outpaced CRISPR Therapeutics, with its cost of revenue peaking at approximately $1.26 billion in 2023, a staggering 20-fold increase from 2014. In contrast, CRISPR Therapeutics, while showing growth, reached a cost of revenue of around $130 million in 2023, marking a significant rise from its 2014 figure. This comparison highlights Vertex's expansive operational scale and CRISPR's steady growth trajectory. As the biotech sector continues to innovate, these financial insights provide a window into the strategic priorities and market positioning of these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025